Trial Profile

Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs G 207 (Primary)
Indications Anaplastic astrocytoma; Brain cancer; Ependymoma; Germ cell and embryonal neoplasms; Germ cell cancer; Giant cell tumours; Glioblastoma; Glioma; Medulloblastoma; Neuroectodermal tumours; Rhabdoid tumour; Teratoma
Focus Adverse reactions; First in man

Most Recent Events

19 Mar 2025 Status changed from active, no longer recruiting to recruiting.
26 Jun 2024 Planned End Date changed from 1 Sep 2026 to 1 Sep 2027.
26 Jun 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com